FISCHER35.20

Fischer Medical Ventures Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersTARSONSLAXMIDENTLFABTECHGKBMcap ₹2,304 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations23.486.3101.197.781.9
Other Income7.52.51.11.31.5
Total Income30.988.8102.299.083.4
Expenses
+ Cost of Materials Consumed7.60.10.062.144.0
+ Purchases of Stock-in-Trade0.011.257.86.922.1
+ Changes in Inventories5.01.3-8.9-0.5-7.9
+ Employee Benefit Expense3.23.74.24.04.5
+ Finance Costs0.70.90.63.63.5
+ Depreciation & Amortisation0.80.50.80.91.4
+ Other Expenses3.553.626.524.27.9
Total Expenses20.671.580.9101.375.6
EBITDA4.316.321.61.011.3
EBIT3.515.720.80.19.9
Profit
PBT before Exceptional Items10.317.321.2-2.37.8
Pretax Income10.317.321.2-2.37.8
+ Current Tax4.42.81.77.72.4
+ Deferred Tax0.80.60.2-2.91.6
Tax Expense5.23.42.04.94.0
+ Share of Associates & JVs-0.1-0.0-0.1-0.00.0
Net Income5.013.919.2-7.13.8
+ Net Income — Continuing Ops5.113.919.3-7.13.8
+ Other Comprehensive Income0.00.10.00.00.0
Total Comprehensive Income5.014.019.2-7.13.8
Net Income to Common-0.00.1
Minority Interest-0.0-0.1
Per Share
Basic EPS0.772.150.30-0.110.06
Diluted EPS0.762.110.290.100.05
Other Comprehensive Income — detail
+ Other Comprehensive Income0.10.00.00.0
+ Items NOT to be Reclassified to P&L0.10.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations0.772.150.30-0.110.06
Diluted EPS — Continuing Operations0.762.110.290.100.05
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit10.973.652.229.323.7
Gross Margin %46.5085.3151.6429.9528.94
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)10.317.321.2-2.37.8
Net Income Adj (tax-effected)5.013.919.2-7.13.8
EPS Adj0.772.150.30-0.110.06
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.001.001.001.001.00
Paid Up Equity Capital64.964.964.965.565.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.